reason report
recap zilucoplan hone neuro gmg imnm studi
bottom line leverag posit data gener
imnm becom next program rarx paroxysm nocturn
hemoglobinuria pnh de-priorit similar gmg
imnm includ role complement deposit diseas
pathophysiolog de-risk imnm view gmg imnm
studi expect begin take rarx one step closer
commerci stage meanwhil earli stage develop weekli less
frequent formul zilucoplan -- success -- could import
life-cycl manag lcm strategi competit intensifi
complement-medi diseas reiter op pt lower
recent equiti rais
gmg studi initi discuss initi
link zilucoplan shown effect gmg pt view
clinic profil competit ad conveni factor
pt may appeal pt receiv standard care soc
approv agent wherea anti-fcrn antibodi enter
competit dynam gmg believ inhibit remain
attract given physician experi mechan track
record favor safeti profil soliri op back
posit data rarx plan initi rais studi
-- assum posit outcom gmg stand becom first
commerci oppti rarx
imnm studi also initi expand zilucoplan
success gmg rarx recent announc plan pursu imnm
anoth neurolog indic shown involv complement deposit
muscl fiber learn medacorp kol link
high unmet need exacerb lack approv agent variabl
efficaci rituximab nationwid shortag ivig upcom
studi short durat week batteri
function assess could provid import insight clinic
meaning endpoint use subsequ pivot trial like
rais studi imnm studi also expect initi
look beyond daili zilucoplan weekli less frequent
formul licens agreement camuru fluidcryst
rarx two technolog potenti develop less frequent
administ zilucoplan weekli less frequent administr may
increment valu improv pt strateg rarx
competitor emerg proprietari formul long-act
blend revenu multipl
analysi dcf disc rate
net debt total capit
gener per share
year price history/av daili volume mil rarx
compani inform svb leerink llc research
revenu million
pleas refer page import disclosur price chart analyst certif
lead candid zilucoplan phase asset gener myasthenia gravi gmg trial
initi paroxysm nocturn hemoglobinuria pnh trial initi tbd immune-
mediat necrot myopathi imnm trial initi next indic
estim gmg market opportun us eu think zilucoplan approv
could captur peak
imnm could leverag rarx grow neurolog footprint approv estim
although pnh offer lucr opportun svb leerink estim peak
op ascrib pnh valu zilucoplan pend futur updat
base present data odd success gmg pnh imnm
ww though assum revenu contribut pnh
soliri approv suggest zilucoplan opportun beyond gmg pnh
daili subcutan sq near term oral administr medium-to-long term
deliv efficaci patient-friendli conveni
mrna display extrem divers platform churn addit therapeut candid
longer term ra macrocycl peptid may overcom technic challeng antibodi
address non-soliris-approv diseas
deriv one-year pt rarx base blend dcf analysi
revenu multipl analysi assign valu probability-weight sale zilucoplan
gener myasthenia gravi po gmg immune-medi necrot myopathi
po imnm meanwhil despit encourag data ascrib valu
zilucoplan paroxysm nocturn hemoglobinuria pnh addit indic and/or drug
candid may repres upsid estim matur clinical-stag compani use
discount rate termin growth rate repres market capit
clinical-stag compani risk rarx includ clinic regulatori financi
lead asset zilucoplan add signific binari risk head data readout even
though evalu multipl indic guarante program
despit alxn posit preced target complement protein success
particular indic may translat success indic
approv gmg rate zilucoplan adopt earlier treatment set address
legaci entrant entrench well-posit compet directli rarx
clinic risk associ subsequ clinic candid
total incom expens
chang cash
proce common stock
proce convert note/debt
discount rate/cost equiti
